Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2024 Financial Results Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON, Mass – May 9, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced it ...